Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1671812 | 0.88 | HTT (0.79) | HTTALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL10732007 | 0.87 | ALDH1A1 (0.77) | HTTALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL11161146 | 0.86 | HTT (0.76) | HTTALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL11102314 | 0.86 | HTT (0.76) | HTTALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL11108796 | 0.86 | HTT (0.75) | HTTALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL11102744 | 0.85 | ALDH1A1 (0.78) | HTTALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL10502203 | 0.85 | ALDH1A1 (0.97) | HTTALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL11105710 | 0.84 | HTT (0.73) | HTTALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL11161561 | 0.84 | HTT (0.73) | HTTALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL1972566 | 0.84 | ALDH1A1 (0.75) | HTTALDH1A1SMN1; SMN2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951999-B2 | Compounds | OREXO AB (SE) | 2015-02-10 | — | — | US | disclosed |
| US-8951999-B2 | Compounds | OREXO AB (SE) | 2015-02-10 | — | — | US | disclosed |
| EP-2491007-B1 | Inhibitors of the microsomal prostaglandin E2 synthase-1 | BOEHRINGER INGELHEIM INT (DE) | 2013-09-25 | — | — | EP | disclosed |
| EP-2491007-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| EP-0063826-B1 | 2-AMINO-BENZOIC-ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINES OR INTERMEDIATES | Dr. Karl Thomae GmbH (DE) | 1984-12-05 | — | — | EP | disclosed |
| EP-0023569-B1 | DERIVATIVES OF CARBOXYLIC ACIDS, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1983-06-22 | — | — | EP | disclosed |
| EP-0063826-A2 | 2-Amino-benzoic-acid derivatives, their preparation and their use as medicines or intermediates | Dr. Karl Thomae GmbH (DE) | 1982-11-03 | — | — | EP | disclosed |
| EP-0023569-A1 | Derivatives of carboxylic acids, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263556-A1 | New Compounds | PTGES, PTGER1, PTGS1 | HTT 4710/4885ALDH1A1 228/4885SMN1; SMN2 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.